AUROPHARMA.NSAUROPHARMA.NSNSE
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank69
3Y CAGR-0.7%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-0.7%/yr
Quarterly compound
Percentile
P69
Within normal range
vs 3Y Ago
1x
Modest growth
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 6.01% |
| Q3 2025 | 28.37% |
| Q2 2025 | -0.42% |
| Q1 2025 | 9.05% |
| Q4 2024 | 1.99% |
| Q3 2024 | 3.50% |
| Q2 2024 | -6.52% |
| Q1 2024 | 15.87% |
| Q4 2023 | 3.63% |
| Q3 2023 | 0.32% |
| Q2 2023 | -3.42% |
| Q1 2023 | 6.94% |
| Q4 2022 | 6.13% |
| Q3 2022 | -1.33% |
| Q2 2022 | -9.95% |
| Q1 2022 | 12.49% |
| Q4 2021 | 1.17% |
| Q3 2021 | -1.27% |
| Q2 2021 | -10.95% |
| Q1 2021 | 10.92% |
| Q4 2020 | -3.42% |
| Q3 2020 | 2.69% |
| Q2 2020 | -9.24% |
| Q1 2020 | 22.64% |
| Q4 2019 | 2.65% |
| Q3 2019 | -0.34% |
| Q2 2019 | -10.10% |
| Q1 2019 | 33.50% |
| Q4 2018 | 3.89% |
| Q3 2018 | 4.92% |
| Q2 2018 | -13.83% |
| Q1 2018 | 27.95% |
| Q4 2017 | 4.23% |
| Q3 2017 | 5.82% |
| Q2 2017 | -9.36% |
| Q1 2017 | 21.35% |
| Q4 2016 | 4.47% |
| Q3 2016 | -1.27% |
| Q2 2016 | -6.05% |
| Q1 2016 | 14.68% |